KALV - Company ID 0001348911
The table below shows KalVista Pharmaceuticals, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|
| Revenue | $40.86M | $13.70M | $1.40M | - | - | $0.00 |
| Cost of revenue | $3.09M | $1.23M | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $12.42M | $11.99M | $15.16M | $14.17M | $12.59M | $18.68M |
KalVista Pharmaceuticals, Inc. reported annual revenue of $50.00M for fiscal year 2024. That is up 294.0% from $12.69M in fiscal 2020. Over the 6 fiscal years shown, annual revenue grew from $2.13M (FY 2016) to $50.00M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $48.80M |
| $46.52M |
| $44.68M |
| $35.53M |
| $30.35M |
| $24.80M |
| Operating income | -$23.44M | -$46.05M | -$59.01M | -$49.71M | -$42.94M | -$43.48M |
| Income tax | $0.00 | $2.16M | $2.16M | $4.25M | $4.25M | $0.00 |
| Net income | -$23.49M | -$49.48M | -$57.60M | -$51.84M | -$48.51M | -$39.08M |
| EPS (diluted) | -$0.43 | -$0.92 | -$1.12 | -$0.98 | -$0.92 | -$0.84 |